John Chester

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

Alison Birtle, Mark Johnson, John Chester et al. · The Lancet · 2020 · 527 citations · Full text

Medicine, Oncology, Urology +15

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

Cora N. Sternberg, Iwona Skoneczna, J. Martijn Kerst et al. · The Lancet Oncology · 2014 · 387 citations

Medicine, Oncology, Urology +11

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer

Thomas Powles, Robert Huddart, Tony Elliott et al. · Journal of Clinical Oncology · 2017 · 202 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger et al. · Clinical Cancer Research · 2012 · 187 citations · Full text

Medicine, Oncology, Pharmacology +15

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

Fiona R. Lamont, Darren C. Tomlinson, Patricia A. Cooper et al. · British Journal of Cancer · 2010 · 178 citations · Full text

Medicine, Oncology, Pharmacology +13